Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of LY4100511 with Itraconazole, Fluconazole, or Carbamazepine in Healthy Adults
NCT06345794Phase 1Completed
- Sponsor
- DICE Therapeutics
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of simepdekinra in plaque psoriasis (3 cohorts), sponsored by DICE Therapeutics. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration Versus Time Curve From Zero to Last Measurable Concentration and 1 more. Started Apr 2024; status: completed.
02
Drugs
simepdekinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06345794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345794.